FDA Approved Indications for this Orphan Drug:

For the use of Acetadote(registered TM) Injection, administered intravenously within 8 to 10 hours after ingestion of a potentially heptotoxic quantity of acetaminophen, to prevent or lessen hepatic injur

FDA Marketing Approval issued as of:
01/23/2004

Orphan Drug exclusivity ends on:
01/23/2011
Company Making and Marketing this drug:
Cumberland Pharmaceuticals, Inc.

FDA Designation Date:
10/19/01

FDA Drug Designation:
For the intravenous treatment of moderate to severe acetaminophen overdose